Log In Get Started
Analyst Ratings February 20, 2026

Wedbush Begins Coverage of Burford Capital, Assigns Outperform and $14 Target

Analyst frames Burford as a unique public play on litigation finance; BofA also kicks off coverage with a buy rating

By Jordan Park BUR
Wedbush Begins Coverage of Burford Capital, Assigns Outperform and $14 Target
BUR

Wedbush has opened coverage on Burford Capital (NYSE: BUR) with an outperform rating and a $14.00 price target, calling the company the only pure-play litigation finance firm trading publicly and noting asymmetric return potential tied in part to the YPF dispute. Separately, BofA Securities has initiated coverage with a buy rating, placing a $14.55 target on the New York-listed shares and 1,062 pence on the London-listed stock.

Key Points

  • Wedbush initiated coverage on Burford Capital with an outperform rating and a $14.00 price target; the firm views Burford as the only publicly traded pure-play litigation finance company.
  • Wedbush cited asymmetric return potential for Burford shares, specifically noting the possibility of a significant payoff from the YPF dispute.
  • BofA Securities also began coverage with a buy rating, assigning a $14.55 target to the New York-listed shares and 1,062 pence to the London-listed shares, reflecting another positive analyst perspective.

Wedbush has started research coverage on Burford Capital (NYSE: BUR), awarding the litigation finance firm an outperform rating and setting a $14.00 price objective, according to a report released Thursday. The brokerage described Burford as a distinctive special situation because it is the only publicly traded company focused exclusively on litigation finance.

In its write-up, Wedbush highlighted what it called asymmetric return potential for Burford shareholders, pointing to the possibility of a substantial payoff tied to the companys exposure to the YPF dispute. The firms $14 price target encapsulates its valuation view for Burfords publicly listed shares.

Burford Capital operates within the litigation finance sector, supplying capital to corporations and law firms to underwrite legal matters. That operational focus is central to how analysts are valuing the firm and assessing potential upside and downside outcomes.

In related analyst activity, BofA Securities also initiated coverage on Burford Capital and assigned a buy rating. BofAs valuation places the New York-listed shares at a $14.55 target and the London-listed shares at 1,062 pence. The firms conclusions signal a constructive view of Burfords valuation relative to prevailing market prices, according to the report.

Both broker notes underscore investor interest in how a publicly traded, pure-play litigation financier is valued by the market. Wedbushs emphasis on a potential windfall from an ongoing legal dispute and BofAs slightly higher price objective illustrate differing but generally favorable analyst perspectives.

For investors and market participants, these initiations provide fresh third-party valuations to weigh alongside existing market prices. The analyst reports reiterate Burfords identity as a niche financial-services firm with case-specific catalysts that can materially affect outcomes for shareholders.

Because these coverage starts and price targets reflect analysts assumptions about case outcomes and company valuation, market participants may use them as part of broader decision-making rather than definitive forecasts.

Risks

  • Outcome uncertainty tied to the YPF dispute - the potential windfall cited by Wedbush is contingent on the disputes resolution and therefore uncertain.
  • Valuation divergence among analysts - differing price targets from Wedbush and BofA highlight uncertainty around the appropriate valuation for a pure-play litigation finance firm.
  • Sector-specific exposure - Burfords focus on litigation finance concentrates company performance around legal case outcomes and the broader market for legal financing.

More from Analyst Ratings

BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026 Supreme Court Ruling Boosts Steve Madden Outlook, Analysts Say Feb 20, 2026 UBS Lowers Carvana Price Target Citing Higher Costs, Keeps Buy Rating Feb 20, 2026